Exited position

George Soros’s Ionis Pharmaceuticals Inc (IONS) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Soros Fund ManagementVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ4 2015Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares12.00KHighest verified quarter-end share count
Quarters reported3Verified quarters with shares above zero
What happened?

Soros Fund Management first reported Ionis Pharmaceuticals Inc in Q4 2015. The latest verified relationship event shows that Soros Fund Management sold the entire position in Q3 2017, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q3 2017
Sold the entire position−10.70K shares · No shares reported at quarter-end
Q2 2017
New position+10.70K shares · 10.70K shares reported
Filing context

Quarter-end price $50.84 · Estimated holding basis $50.84

Q1 2017
Sold the entire position−4.30K shares · No shares reported at quarter-end
Q4 2016
New position+4.30K shares · 4.30K shares reported
Filing context

Quarter-end price $47.91 · Estimated holding basis $47.91

Q1 2016
Sold the entire position−12.00K shares · No shares reported at quarter-end
Q4 2015
New position+12.00K shares · 12.00K shares reported
Filing context

Quarter-end price $61.92 · Estimated holding basis $61.92

Portfolio importance

How important was Ionis Pharmaceuticals Inc in Soros Fund Management’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.0%Q2 2017
Last reported rank#112of 187 reported positions
Peak portfolio weight0.0%Q2 2017
Best historical rank#112Q2 2017
At peak importanceQ2 2017
IONS
0.0%
Largest holding
18.6%
Cross-investor discovery

Who else owns Ionis Pharmaceuticals Inc?

Also reported by 2 other tracked investors in their latest verified filings.

Cathie WoodARK Investment Management
IONS0.2% of reported portfolio
Joel GreenblattGotham Asset Management
IONS0.0% of reported portfolio
Explore Ionis Pharmaceuticals Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$44.842026-09-16

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

This tracker follows Soros Fund Management LLC’s Form 13F disclosures—not George Soros’s personal brokerage account. George Soros founded the firm; its current CEO and chief investment officer is Dawn Fitzpatrick. Form 13F does not reveal exact trade dates, execution prices or the purpose of an option position.